PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk
DOI:
https://doi.org/10.12775/QS.2024.35.56299Keywords
PCSK9 inhibitors, cardiovascular disease, dyslipidemiaAbstract
Introduction: Abnormal blood cholesterol levels in patients with increased cardiovascular risk have a worse prognosis for patient survival. Treating dyslipidemia is important because it can improve patient comfort and safety. It sometimes happens that currently used drugs to lower cholesterol are not effective - patients develop tolerance or experience serious side effects. For this reason, scientists are looking for new drugs with a different mechanism of action. An example of such a group of drugs are PCSK9 inhibitors used to treat dyslipidemia. In this paper, we will look at the effectiveness of currently used PCSK9 inhibitors, but also at the potential risks associated with their use.
Material and methods: We searched for materials for this work in the Pubmed and Google Scholar databases using the keywords: "dyslipidemia", "cardiovascular disease", "PCSK9 inhibitors", "statins". Then we analyzed the selected materials.
Aim of the study: Evaluation of the
Conclusion: PCSK9 inhibitors are drugs that are very effective in lowering low-density lipoprotein (LDL-C), while reducing cardiovascular risk and potentially having long-lasting effects. Scientists are looking for new PCSK9 inhibitors with different mechanisms of action, which will be an even more effective therapy in lowering LDL-C.
References
J. Miao, X. Zang, X. Cui, i J. Zhang, „Autophagy, Hyperlipidemia, and Atherosclerosis”, Adv. Exp. Med. Biol., t. 1207, s. 237–264, 2020, doi: 10.1007/978-981-15-4272-5_18.
J. Palasubramaniam, X. Wang, i K. Peter, „Myocardial Infarction—From Atherosclerosis to Thrombosis”, Arterioscler. Thromb. Vasc. Biol., t. 39, nr 8, s. e176–e185, sie. 2019, doi: 10.1161/ATVBAHA.119.312578.
Y.-L. Chow, L. K. Teh, L. H. Chyi, L. F. Lim, C. C. Yee, i L. K. Wei, „Lipid Metabolism Genes in Stroke Pathogenesis: The Atherosclerosis”, Curr. Pharm. Des., t. 26, nr 34, s. 4261–4271, 2020, doi: 10.2174/1381612826666200614180958.
T. Liu, D. Zhao, i Y. Qi, „Global Trends in the Epidemiology and Management of Dyslipidemia”, J. Clin. Med., t. 11, nr 21, Art. nr 21, sty. 2022, doi: 10.3390/jcm11216377.
L.-Y. Liu i in., „Epidemic trends of dyslipidemia in young adults: a real-world study including more than 20,000 samples”, Lipids Health Dis., t. 22, nr 1, s. 108, lip. 2023, doi: 10.1186/s12944-023-01876-2.
P. Samantha Karr, „Epidemiology and Management of Hyperlipidemia”, t. 23, cze. 2017, Dostęp: 19 lipiec 2024. [Online]. Dostępne na: https://www.ajmc.com/view/epidemiology-and-management-of-hyperlipidemia-article
N. He i H. Ye, „Exercise and Hyperlipidemia”, w Physical Exercise for Human Health, J. Xiao, Red., Singapore: Springer Nature, 2020, s. 79–90. doi: 10.1007/978-981-15-1792-1_5.
Z. Li i in., „Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018”, Lipids Health Dis., t. 21, nr 1, s. 111, paź. 2022, doi: 10.1186/s12944-022-01721-y.
K. J. Ezeh, O. Ezeudemba, K. J. Ezeh, i O. Ezeudemba, „Hyperlipidemia: A Review of the Novel Methods for the Management of Lipids”, Cureus, t. 13, lip. 2021, doi: 10.7759/cureus.16412.
S. K. Majanović i in., „Dyslipidemia: Current Perspectives and Implications for Clinical Practice”, w Management of Dyslipidemia, IntechOpen, 2021. doi: 10.5772/intechopen.98386.
Y. Chang, S. Eom, M. Kim, i T.-J. Song, „Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review”, Med. Kaunas Lith., t. 59, nr 4, s. 776, kwi. 2023, doi: 10.3390/medicina59040776.
R.-G. Mihăilă, „Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review”, Curr. Cardiol. Rev., t. 16, nr 1, s. 36–47, luty 2020, doi: 10.2174/1573403X15666190522100041.
A. Yadav, V. Sawant, V. Singh Bedi, i K. Yadav, „Dyslipidemia and peripheral arterial disease”, Indian Heart J., t. 76, nr Suppl 1, s. S86–S89, mar. 2024, doi: 10.1016/j.ihj.2024.01.010.
L. Tokgozoglu i M. Kayikcioglu, „Familial Hypercholesterolemia: Global Burden and Approaches”, Curr. Cardiol. Rep., t. 23, nr 10, s. 151, wrz. 2021, doi: 10.1007/s11886-021-01565-5.
S. Singh i V. Bittner, „Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening”, Curr. Atheroscler. Rep., t. 17, nr 2, s. 3, sty. 2015, doi: 10.1007/s11883-014-0482-5.
M. P. McGowan, S. H. Hosseini Dehkordi, P. M. Moriarty, i P. B. Duell, „Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia”, J. Am. Heart Assoc., t. 8, nr 24, s. e013225, grudz. 2019, doi: 10.1161/JAHA.119.013225.
C. L. Robbins, P. M. Dietz, J. Bombard, M. Tregear, S. M. Schmidt, i S. J. Tregear, „Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age”, Prev. Chronic. Dis., t. 8, nr 6, s. A123, lis. 2011.
S. Agrawal, J. J. Zaritsky, A. Fornoni, i W. E. Smoyer, „Dyslipidaemia in nephrotic syndrome: mechanisms and treatment”, Nat. Rev. Nephrol., t. 14, nr 1, s. 57–70, sty. 2018, doi: 10.1038/nrneph.2017.155.
C. R. Sirtori, „The pharmacology of statins”, Pharmacol. Res., t. 88, s. 3–11, paź. 2014, doi: 10.1016/j.phrs.2014.03.002.
B. A. P. Phan, T. D. Dayspring, i P. P. Toth, „Ezetimibe therapy: mechanism of action and clinical update”, Vasc. Health Risk Manag., t. 8, s. 415–427, 2012, doi: 10.2147/VHRM.S33664.
N. S. Ghonem, D. N. Assis, i J. L. Boyer, „On Fibrates and Cholestasis: A review”, Hepatol. Baltim. Md, t. 62, nr 2, s. 635–643, sie. 2015, doi: 10.1002/hep.27744.
D. R. Moazzeni, „PCSK9 Inhibitors: The New Frontier in Cholesterol Management”, Heartcare Sydney. Dostęp: 20 lipiec 2024. [Online]. Dostępne na: https://heartcare.sydney/pcsk9-inhibitors/
C. Liu i in., „PCSK9 Inhibition: From Current Advances to Evolving Future”, Cells, t. 11, nr 19, Art. nr 19, sty. 2022, doi: 10.3390/cells11192972.
P. Gennemark i in., „An oral antisense oligonucleotide for PCSK9 inhibition”, Sci. Transl. Med., t. 13, nr 593, s. eabe9117, maj 2021, doi: 10.1126/scitranslmed.abe9117.
Y. N. Lamb, „Inclisiran: First Approval”, Drugs, t. 81, nr 3, s. 389–395, 2021, doi: 10.1007/s40265-021-01473-6.
N. F. Ilahibaks i in., „Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes”, J. Extracell. Vesicles, t. 13, nr 1, s. e12389, sty. 2024, doi: 10.1002/jev2.12389.
T. Mitchell i in., „Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering”, J. Pharmacol. Exp. Ther., t. 350, nr 2, s. 412–424, sie. 2014, doi: 10.1124/jpet.114.214221.
S. U. Khan i in., „PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis”, BMJ, t. 377, s. e069116, maj 2022, doi: 10.1136/bmj-2021-069116.
E. Voutyritsa i in., „PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance”, Vivo Athens Greece, t. 35, nr 1, s. 61–68, 2021, doi: 10.21873/invivo.12232.
H. E. Ison, S. L. Clarke, i J. W. Knowles, „Familial Hypercholesterolemia”, w GeneReviews®, M. P. Adam, J. Feldman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, L. J. Bean, K. W. Gripp, i A. Amemiya, Red., Seattle (WA): University of Washington, Seattle, 1993. Dostęp: 20 lipiec 2024. [Online]. Dostępne na: http://www.ncbi.nlm.nih.gov/books/NBK174884/
M. J. Péč i in., „The Anti-Thrombotic Effects of PCSK9 Inhibitors”, Pharmaceuticals, t. 16, nr 9, Art. nr 9, wrz. 2023, doi: 10.3390/ph16091197.
M. L. O’Donoghue i in., „Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease”, Circulation, t. 146, nr 15, s. 1109–1119, paź. 2022, doi: 10.1161/CIRCULATIONAHA.122.061620.
F. Mach i in., „2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)”, Eur. Heart J., t. 41, nr 1, s. 111–188, sty. 2020, doi: 10.1093/eurheartj/ehz455.
S. J. Nicholls i in., „Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction”, JACC Cardiovasc. Imaging, t. 15, nr 7, s. 1308–1321, lip. 2022, doi: 10.1016/j.jcmg.2022.03.002.
L. Räber i in., „Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial”, JAMA, t. 327, nr 18, s. 1771–1781, maj 2022, doi: 10.1001/jama.2022.5218.
S. J. Nicholls i in., „Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial”, JAMA, t. 316, nr 22, s. 2373–2384, grudz. 2016, doi: 10.1001/jama.2016.16951.
R. S. Rosenson, A. Tate, P. Mar, O. Grushko, Q. Chen, i S. N. Goonewardena, „Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects”, Atherosclerosis, t. 392, maj 2024, doi: 10.1016/j.atherosclerosis.2024.117529.
G. G. Schwartz i in., „Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome”, N. Engl. J. Med., t. 379, nr 22, s. 2097–2107, lis. 2018, doi: 10.1056/NEJMoa1801174.
Y. Zhang i in., „Inclisiran: a new generation of lipid-lowering siRNA therapeutic”, Front. Pharmacol., t. 14, s. 1260921, 2023, doi: 10.3389/fphar.2023.1260921.
K. K. Ray i in., „Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol”, N. Engl. J. Med., t. 382, nr 16, s. 1507–1519, kwi. 2020, doi: 10.1056/NEJMoa1912387.
S. Yamashita i in., „Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15”, J. Atheroscler. Thromb., t. 31, nr 6, s. 876–903, cze. 2024, doi: 10.5551/jat.64454.
K. K. Ray i in., „Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial”, Lancet Diabetes Endocrinol., t. 11, nr 2, s. 109–119, luty 2023, doi: 10.1016/S2213-8587(22)00353-9.
K. S. Makarova i in., „Evolution and classification of the CRISPR-Cas systems”, Nat. Rev. Microbiol., t. 9, nr 6, s. 467–477, cze. 2011, doi: 10.1038/nrmicro2577.
R. G. Lee i in., „Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models”, Circulation, t. 147, nr 3, s. 242–253, sty. 2023, doi: 10.1161/CIRCULATIONAHA.122.062132.
K. Musunuru i in., „In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates”, Nature, t. 593, nr 7859, s. 429–434, maj 2021, doi: 10.1038/s41586-021-03534-y.
G. Grześk i in., „Safety of PCSK9 inhibitors”, Biomed. Pharmacother., t. 156, s. 113957, grudz. 2022, doi: 10.1016/j.biopha.2022.113957.
R. P. Giugliano i in., „Cognitive Function in a Randomized Trial of Evolocumab”, N. Engl. J. Med., t. 377, nr 7, s. 633–643, sie. 2017, doi: 10.1056/NEJMoa1701131.
„Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial - ClinicalKey”. Dostęp: 24 lipiec 2024. [Online]. Dostępne na: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717303133?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213858717303133%3Fshowall%3Dtrue&referrer=https:%2F%2Fwww.sciencedirect.com%2F
M. J. Koren i in., „Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study”, JAMA Cardiol., t. 2, nr 6, s. 598–607, cze. 2017, doi: 10.1001/jamacardio.2017.0747.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Radosław Szydłowski, Magdalena Bodera, Hanna Porwolik, Agata Porwolik, Patrycja Pabis, Agnieszka Porwolik, Dominik Rabstein, Piotr Gościniewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 74
Number of citations: 0
